Clinical Trial

A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma

Name: A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma — clinical trial record (NCT07150377)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy of Iparomlimab and Tuvonralimab in combination with Lenvatinib and TACE for advanced hepatocellular carcinoma by assessing Progression-Free Survival (PFS).

Trial Details

NCT Number	NCT07150377
Lead Sponsor	The Second Affiliated Hospital of Shandong First Medical University
Conditions	Hepatocellular Carcinoma (HCC)
Enrollment	41 participants
Start Date	2025-08-24
Primary Completion	2026-08-24 (estimated)
Study Completion	2028-08-24 (estimated)
Updated on ClinicalTrials.gov	2025-09-02